NYSE$COR
Cencora Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Cencora reported strong first quarter results, with revenue up 15.0% year-over-year and adjusted diluted EPS increasing by 21.0%.
Cencora's first quarter fiscal year 2024 showed strong performance with a 15.0% increase in revenue to $72.3 billion. GAAP diluted EPS was $2.98, while adjusted diluted EPS increased to $3.28. The company has raised its adjusted diluted EPS guidance for fiscal year 2024 to a range of $13.25 to $13.50.
- Revenue increased by 15.0% year-over-year to $72.3 billion.
- GAAP diluted EPS was $2.98, compared to $2.33 in the prior year.
- Adjusted diluted EPS increased by 21.0% to $3.28.
- Adjusted diluted EPS guidance raised to $13.25 to $13.50 for fiscal year 2024.
Headline financials
Revenue & EPS history
Cencora · Revenue · Quarterly
$72.3B
Forward guidance
Cencora updated its fiscal year 2024 financial guidance to reflect its expected strong business performance for the full fiscal year, including the incremental contributions from commercial COVID-19 vaccine distribution in the first quarter.
Tailwinds
- Revenue growth to be in the range of 10 to 12 percent, up from the previous range of 7 to 10 percent
- U.S. Healthcare Solutions revenue growth to be in the range of 11 to 13 percent, up from the previous range of 7 to 10 percent
- Adjusted diluted earnings per share to be in the range of $13.25 to $13.50, up from the previous range of $12.70 to $13.00
- Adjusted consolidated operating income growth to be in the range of 8 to 10 percent, up from the previous range of 4 to 6 percent
- International Healthcare Solutions segment operating income growth to be in the range of 5 to 8 percent, up from the previous range of 1 to 4 percent
Headwinds
- The Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable significance of which cannot be determined, is not available or cannot be reasonably estimated.
- LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company’s control
- acquisition-related intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.
- the timing and amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable and cannot be reasonably estimated.
- The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable and cannot be reasonably estimated.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
-0.1%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+1.4%
Avg return
30 days after
48%
35 / 73 earnings
Positive
+7.8%
Q2 2019
Best reaction
-18.4%
Q2 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | -18.4% | -16.6% | -10.1% | |
| Q1 2026 | -5.9% | +0.4% | -0.9% | |
| Q4 2025 | +2.9% | +5.8% | -1.4% | |
| Q3 2025 | -2.9% | -0.6% | +0.1% | |
| Q2 2025 | +4.6% | -4.3% | -0.6% | |
| Q1 2025 | +0.7% | -2.1% | +1.2% | |
| Q4 2024 | +5.9% | +6.5% | +4.0% | |
| Q3 2024 | +5.8% | +4.4% | +3.7% | |
| Q2 2024 | -6.0% | -6.3% | -5.2% | |
| Q1 2024 | +7.4% | +6.2% | +7.5% | |
| Q4 2023 | +4.2% | +4.7% | +9.0% | |
| Q3 2023 | +1.2% | -1.3% | -7.5% | |
| Q2 2023 | +0.1% | +0.7% | +3.5% | |
| Q1 2023 | -6.2% | -8.6% | -7.6% | |
| Q4 2022 | +4.4% | +3.1% | +12.4% | |
| Q3 2022 | -2.5% | -1.5% | +3.4% | |
| Q2 2022 | +2.9% | +4.4% | -2.5% | |
| Q1 2022 | +0.2% | +1.3% | +7.0% | |
| Q4 2021 | -0.6% | -2.8% | -9.0% | |
| Q3 2021 | -1.5% | -2.8% | +1.2% | |
| Q2 2021 | -6.5% | -2.1% | -7.1% | |
| Q1 2021 | +3.9% | +1.8% | -0.7% | |
| Q4 2020 | -1.0% | +4.8% | -1.9% | |
| Q3 2020 | -3.0% | -1.6% | -7.7% | |
| Q2 2020 | +3.0% | +3.6% | +15.8% | |
| Q1 2020 | -4.8% | -2.0% | -6.2% | |
| Q4 2019 | +1.6% | +1.0% | +4.2% | |
| Q3 2019 | +3.8% | -3.5% | -5.6% | |
| Q2 2019 | +7.8% | +5.5% | +6.1% | |
| Q1 2019 | +6.7% | +9.2% | +5.7% | |
| Q4 2018 | -2.3% | +0.3% | -2.9% | |
| Q3 2018 | +1.9% | +5.0% | +13.2% | |
| Q2 2018 | -4.3% | -5.1% | -6.6% | |
| Q1 2018 | +2.5% | -2.9% | +4.7% | |
| Q4 2017 | -2.4% | -2.2% | +10.9% | |
| Q3 2017 | -11.4% | -12.0% | -12.1% | |
| Q2 2017 | +3.9% | +5.9% | +13.2% | |
| Q1 2017 | +6.0% | +6.8% | +9.9% | |
| Q4 2016 | +3.6% | +3.1% | +12.9% | |
| Q3 2016 | +5.1% | +4.5% | +1.9% | |
| Q2 2016 | -9.2% | — | — | |
| Q1 2016 | -3.7% | — | — | |
| Q4 2015 | -1.0% | — | — | |
| Q3 2015 | -5.4% | — | — | |
| Q2 2015 | +1.9% | — | — | |
| Q1 2015 | +0.4% | — | — | |
| Q4 2014 | +7.1% | — | — | |
| Q3 2014 | +3.7% | — | — | |
| Q2 2014 | -3.1% | — | — | |
| Q1 2014 | -4.3% | — | — | |
| Q4 2013 | +1.8% | — | — | |
| Q3 2013 | -0.0% | — | — | |
| Q2 2013 | -4.6% | — | — | |
| Q1 2013 | -5.1% | — | — | |
| Q4 2012 | -0.6% | — | — | |
| Q3 2012 | +2.7% | — | — | |
| Q2 2012 | -1.2% | — | — | |
| Q1 2012 | +2.4% | — | — | |
| Q4 2011 | -1.0% | — | — | |
| Q3 2011 | -0.5% | — | — | |
| Q2 2011 | +2.9% | — | — | |
| Q1 2011 | +0.5% | — | — | |
| Q4 2010 | -0.5% | — | — | |
| Q3 2010 | -0.7% | — | — | |
| Q2 2010 | +1.0% | — | — | |
| Q1 2009 | -1.7% | — | — | |
| Q1 2010 | +1.2% | — | — | |
| Q4 2009 | -0.6% | — | — | |
| Q2 2009 | -0.6% | — | — | |
| Q4 2007 | -0.6% | — | — | |
| Q3 2008 | -0.5% | — | — | |
| Q3 2009 | -0.5% | — | — | |
| Q4 2008 | -0.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro